Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OA-235i, a PAR2 Inhibitor, in Adults With Nonalcoholic Steatohepatitis

NCT05680233 is registered in ClinicalTrials.gov with Oasis Pharmaceuticals, LLC as lead sponsor.

NCT NCT05680233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05680233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OA-235i, a PAR2 Inhibitor, in Adults With Nonalcoholic Steatohepatitis
Lead sponsor
Oasis Pharmaceuticals, LLC
Phase
Phase 1
Overall status
Completed
Start date
March 6, 2023
Completion date
July 2, 2024
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic fatty liver, nonalcoholic steatohepatitis